Skip to main content

Table 1 Clinical and functional characteristics of the entire IPF population, IPF patients with TT/TG genotype and with GG genotype

From: Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment

  Entire population (n = 88) TT/TG genotype (n = 61) GG genotype (n = 27) p Value
Male, n (%) 71 (81) 49 (80) 22 (81) 0.99
Age at diagnosis, years 70 (44–84) 69 (44–84) 71(50–82) 0.30
Body mass index, kg/m2 26 (19–37) 26 (19–33) 27 (22–37) 0.49
Smoking history, pack years 10 (0–240) 10 (0–50) 30 (0–240) 0.0001
Current, n (%) 7 (8) 5 (8) 2 (7)  
Former, n (%) 59 (67) 38 (62) 21 (78) 0.31
Nonsmokers, n (%) 22 (25) 18 (30) 4 (15)  
Radiological diagnosis, n (%) 49 (56) 29 (48) 20 (74) 0.03
UIP 49 29 20  
Probable UIP 31 24 7 0.03
Indeterminate UIP 8 8 0  
FVC at baseline, L 2.60 (1.20–4.61) 2.68 (1.56–4.36) 2.32 (1.20–4.61) 0.02
FVC at baseline, %pred 77 (47–126) 78 (52–126) 68 (47–118) 0.05
TLC at baseline, %pred 73 (40–96) 73 (45–96) 73 (40–93) 0.37
DLCO at baseline, %pred 56 (7–93) 56 (7–89) 56 (28–93) 0.67
Gastroesophageal reflux, n (%) 32 (36) 23 (38) 9 (33) 0.69
Cardiovascular diseases, n (%) 63 (72) 44 (72) 19 (70) 0.86
Metabolic syndrome, n (%) 37 (42) 25 (41) 12 (44) 0.76
Pirfenidone treatment, n (%) 51 (58) 37 (61) 14 (52) 0.48
Nintedanib treatment, n (%) 37 (42) 24 (39) 13 (48) 0.48
FVC decline in the 1st year– mL 50 (-573–657) 84 (-573–657) 34 (-559–461) 0.54
FVC decline in the 1st year, %pred 1 (-29–21) 1 (-29–21) 0 (-12–16) 0.80
Stable in the 1st year, n (%) 63 (72) 45 (74) 18 (67) 0.60
Progressors in the 1st year, n (%) 25 (28) 16 (26) 9 (33)  
RF on exercise, months 19 (0–89) 21 (0–89) 16 (0–44) 0.13
RF at rest, months 27 (0–110) 31 (5–110) 24 (0–59) 0.04
Nausea or vomiting, n (%) 15 (17) 13 (21) 2 (7) 0.10
Diarrhea, n (%) 16 (18) 12 (20) 4 (15) 0.58
Weight loss, n (%) 25 (28) 19 (31) 6 (22) 0.39
Increase in AST, ALT, n (%) 2 (2) 2 (3) 0 (0) 0.34
Acute exacerbations 5 (6) 3 (5) 2 (7) 0.56
Lung transplant, n (%) 5 (6) 4 (6) 1 (4) 0.17
Death, n (%) 27 (31) 15 (25) 12 (44) 0.06
  1. FVC  forced vital capacity, TLC total lung capacity, DLCO lung diffusion carbon oxide, RF respiratory failure, AST aspartate aminotransferase, ALT alanine aminostransferase. Values are expressed as numbers and (%) or median and ranges as appropriate. Negative values mean improvement of FVC. To compare demographic data and baseline clinical characteristics between TT/GT genotype and GG genotype, Chi square test and Fisher t test (n < 5) for categorical variables and Mann–Whitney U test for continuous variables were used. P-values < 0.05 were considered statistically significant (bold values)